Nebido (Testosterone Undecanoate)

Testosterone undecanoate is a long‑acting ester that, after intramuscular injection, is slowly hydrolyzed to free testosterone. The released testosterone binds to intracellular androgen receptors, influencing gene expression that promotes anabolic processes, suppresses catabolism, and restores physiological androgen activity throughout the body.

The dosing regimen for Nebido is individualized; a qualified prescriber determines the appropriate dose and injection interval based on the patient’s serum testosterone levels, clinical response, and safety monitoring. Typical regimens involve an initial loading dose followed by maintenance injections, but exact amounts must be prescribed by a healthcare professional.

Nebido is intended for use in adult males and is not indicated for women who are pregnant or breastfeeding. Testosterone can cross the placenta and may affect fetal development; therefore, it is contraindicated in pregnancy. Women who are nursing should avoid exposure, as testosterone may be secreted in breast milk.

To place an order, submit an enquiry on the Nebido product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if required—and necessary import documentation.

Nebido’s long‑acting ester provides stable serum testosterone levels for up to 12 weeks after a single intramuscular injection, reducing the frequency of dosing compared with short‑acting formulations such as testosterone enanthate or gels. This can improve adherence, but the choice of therapy depends on patient preference, clinical response, and safety considerations.

Nebido should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use, and discard any vial that shows signs of particulate matter or discoloration.

Nebido is given by deep intramuscular injection, typically into the gluteal muscle, by a qualified healthcare professional. The injection volume and technique follow the prescribing information, and patients should be monitored for injection‑site reactions and systemic effects after administration.

Serious adverse events include polycythemia, which may increase the risk of thrombosis, cardiovascular complications such as myocardial infarction or stroke, and rare cases of hepatotoxicity. Regular monitoring of hematocrit, lipid profile, liver enzymes, and cardiovascular status is essential to detect these risks early.

Nebido is contraindicated in men with known hypersensitivity to testosterone undecanoate, those with prostate or breast cancer, severe untreated sleep apnea, uncontrolled heart failure, or significant erythrocytosis. It should also be avoided in patients receiving androgen‑sensitive therapies or in women who are pregnant or lactating.